Eli Lilly and Company
LLYNYSEHealthcare● Active
$1,131.42
+$6.15(+0.55%)
Market Cap$1.07T
P/E Ratio—
52W High$1166.29
52W Low$623.78
Eli Lilly and Company (LLY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LLY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$8.55
Est. $6.97 · +22.7%
Revenue
$19.80B
Est. $17.82B · +11.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 6-Quarter EPS Beat Streak
LLY reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $8.81 | — | — | — | $20.34B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $6.97 | $8.55 | +22.7% | $19.80B | $17.82B | +11.1% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $6.91 | $7.54 | +9.1% | $19.29B | $17.94B | +7.5% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $5.69 | $7.02 | +23.4% | $17.60B | $16.05B | +9.6% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $5.60 | $6.31 | +12.7% | $15.56B | $14.70B | +5.8% |
| ▲ Q2 FY2025 | May 1, 2025 | $3.26 | $3.34 | +2.5% | $12.73B | $12.67B | +0.5% |
| ▲ Q1 FY2025 | Feb 6, 2025 | $5.03 | $5.32 | +5.8% | $13.53B | — | — |
| ▼ Q4 FY2024 | Oct 30, 2024 | $1.47 | $1.18 | -19.7% | $11.44B | $12.10B | -5.4% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$8.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$8.55
EPS Est.
$6.97
EPS Surpr.
+22.7%
Revenue
$19.80B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$7.54
EPS Est.
$6.91
EPS Surpr.
+9.1%
Revenue
$19.29B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$7.02
EPS Est.
$5.69
EPS Surpr.
+23.4%
Revenue
$17.60B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$6.31
EPS Est.
$5.60
EPS Surpr.
+12.7%
Revenue
$15.56B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$3.34
EPS Est.
$3.26
EPS Surpr.
+2.5%
Revenue
$12.73B
Q1 FY2025
Feb 6, 2025Beat
EPS Actual
$5.32
EPS Est.
$5.03
EPS Surpr.
+5.8%
Revenue
$13.53B
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
$1.18
EPS Est.
$1.47
EPS Surpr.
-19.7%
Revenue
$11.44B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $8.70 | $9.06 | $9.69 | 4 |
| Q3 FY2027 | $10.67 | $11.11 | $11.89 | 8 |
| Q2 FY2027 | $9.92 | $10.33 | $11.06 | 5 |
| Q1 FY2027 | $8.81 | $9.18 | $9.82 | 4 |
| Q4 FY2026 | $9.50 | $9.90 | $10.59 | 4 |
| Q3 FY2026 | $8.91 | $9.41 | $10.50 | 11 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $19.1B | $19.8B | $20.8B | 5 |
| Q3 FY2027 | $25.8B | $26.7B | $28.1B | 5 |
| Q2 FY2027 | $21.0B | $21.6B | $22.8B | 5 |
| Q1 FY2027 | $21.4B | $22.1B | $23.3B | 5 |
| Q4 FY2026 | $22.5B | $23.2B | $24.5B | 5 |
| Q3 FY2026 | $20.8B | $21.6B | $23.0B | 10 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +22.7% | $851.21 | $934.60 | +9.80% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +9.1% | $1,003.46 | $1,107.12 | +10.33% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +23.4% | $813.53 | $844.50 | +3.81% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +12.7% | $746.37 | $640.86 | -14.14% |
| ▲ Q2 FY2025 | May 1, 2025 | +2.5% | $898.95 | $794.10 | -11.66% |
| ▲ Q1 FY2025 | Feb 6, 2025 | +5.8% | $842.18 | $870.37 | +3.35% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -19.7% | $903.58 | $846.83 | -6.28% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +50.8% | $772.14 | $845.31 | +9.48% |
Q2 FY2026+9.80%
Report Date
Apr 30, 2026
EPS Beat/Miss
+22.7%
Price Before
$851.21
Price After
$934.60
Q1 FY2026+10.33%
Report Date
Feb 4, 2026
EPS Beat/Miss
+9.1%
Price Before
$1,003.46
Price After
$1,107.12
Q4 FY2025+3.81%
Report Date
Oct 30, 2025
EPS Beat/Miss
+23.4%
Price Before
$813.53
Price After
$844.50
Q3 FY2025-14.14%
Report Date
Aug 7, 2025
EPS Beat/Miss
+12.7%
Price Before
$746.37
Price After
$640.86
Q2 FY2025-11.66%
Report Date
May 1, 2025
EPS Beat/Miss
+2.5%
Price Before
$898.95
Price After
$794.10
Q1 FY2025+3.35%
Report Date
Feb 6, 2025
EPS Beat/Miss
+5.8%
Price Before
$842.18
Price After
$870.37
Q4 FY2024-6.28%
Report Date
Oct 30, 2024
EPS Beat/Miss
-19.7%
Price Before
$903.58
Price After
$846.83
Q3 FY2024+9.48%
Report Date
Aug 8, 2024
EPS Beat/Miss
+50.8%
Price Before
$772.14
Price After
$845.31
Avg Beat Reaction+1.57%
Avg Miss Reaction-6.28%
Beat Rate7 / 8 quarters
Largest Move-14.14% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LLY ends December
Eli Lilly and Company (LLY) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $8.55 — beating the analyst consensus of $6.97 by +22.7%. LLY has beaten EPS estimates for 6 consecutive quarters. The next LLY earnings date is expected around September 1, 2026.
Each quarter, investors track LLY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LLY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LLY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LLY earnings · 5 questionsEli Lilly and Company's next earnings report is expected around September 1, 2026. LLY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LLY historically reports after market close (AMC).
LLY earnings datewhen is LLY earningsLLY next earnings datewhen does LLY report earningsLLY earnings calendar
▸ Source: FMP · Eli Lilly and Company SEC filings · US GAAP · Eli Lilly and Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026